NorthWest Biotherapeutics Inc (NWBO)

[dennisdave]

Merck will certainly not pay $20B for GBM indication alone. That sort of valuation just doesn’t make sense as it’s a relatively modest market size

well Gilead did pay $21 billion for breast cancer alone and those two cancers are market size speaking similar.

Gilead’s Breast Cancer Drug that Came off a $21 Billion Buyout Finally Gets FDA’s Full Approval